2014 ISPE Investigational Products Conference
Conference Program
Conference Highlights
Exhibit Hall

Why This Conference?

The current competitive and global clinical trial environment is facing new challenges for IP material management, particularly in regard to the interactions with regulatory bodies.

Keeping up with new Clinical Trial and GDP regulations and the developing technologies, systems and processes is the key to ensuring compliance and avoiding costly production delays.

Understand how the experience of participating patients impacts the success of any clinical trial and should have a bigger impact on GMP decisions on clinical materials. Attend this conference to gain first-hand insights and knowledge resulting from the ISPE Patient Survey.

REGISTER NOW » - Early Bird ends 22 August!


Don't forget to attend the additional networking opportunity hosted by the ISPE Spain Affiliate: Quality by Design Seminar, 19 September 2014.



Anthony Moult, EFPIA Representative, Director Clinical Supply Operations, Daiichi-Sankyo, UK

Terry Walsh, Head, Comparator Network, TransCelerate BioPharma Inc., USA

Christoph Honermann, Global Prduct Manager Life Science, DACHSER GmbH & Co. KG, Germany

Belén Escribano Romero, Ph.D. Head of the Pharmaceutical Inspection and Enforcement Department, AEMPS - Spanish Agency for Medicinal Products and Medical Devices, Spain

Jason Wakelin-Smith, GCP & GLP Inspector, MHRA, UK


Chair: Henryk Junker, Senior Manager, Clinical Quality, Allergan Ltd, UK

Massimo Eli, Ph.D., Clinical Supply Regional Lead, MSD Italia SrL, Italy

Karen Gram, Principal Specialist, Novo Nordisk A/S, Denmark

Marianne Oth, Ph.D., Manager, Quality Assurance, Lilly Clinical Operations SA, Belgium

Esther Sadler-Williams, Global Director, Catalent Pharma Solutions, UK

Julian Schulz, Associate Director Clinical Supplies, Takeda Development Centre, UK

Bernd Steffens, Ph.D., Head Global Clinical Trial Supplies Unit, Boehringer Ingelheim Pharma GmbH & Co., Germany

Indicates content available to ISPE members only.